Page 97 - GTM-3-4

Global Translational Medicine Blood parameters for SCLC and AC relapse prognosis

relapse-free survival of patients with stage III non-small cell doi: 10.1007/s12032-012-0352-3
lung cancer after treatment. The role of the concentration of 19. Song X, Chen D, Yuan M, Wang H, Wang Z. Total
blood cells. Lab Diagn Vost Eur. 2022;2:148-162. in Russian.
lymphocyte count, neutrophil-lymphocyte ratio, and
doi: 10.34883/PI.2022.11.2.013 platelet-lymphocyte ratio as prognostic factors in advanced
non-small cell lung cancer with chemoradiotherapy. Cancer
10. Tahanovich AD, Kauhanka NN, Murashka DI, et al.
Preoperative blood markers for prediction of recurrence- Manag Res. 2018;10:6677-6683.
free survival after surgical treatment of patients with doi: 10.2147/CMAR.S188578
stage III lung adenocarcinoma. Rus Clin Lab Diagn.
2022;67(11):640-646. in Russian. 20. Agassandian M, Shurin GV, Ma Y, Shurin MR. C-reactive
protein and lung diseases. Int J Biochem Cell Biol. 2014;53:77-88.
doi: 10.51620/0869-2084-2022-67-11-640-646
doi: 10.1016/j.biocel.2014.05.016
11. Duffy MJ, O’Byrne K. Tissue and blood biomarkers in lung
cancer: A review. Adv Clin Chem. 2018;86:1-21. 21. Huang Q, Diao P, Li CL, et al. Preoperative platelet-
lymphocyte ratio is a superior prognostic biomarker to other
doi: 10.1016/bs.acc.2018.05.001 systemic inflammatory response markers in non-small cell
12. Muley T, Rolny V, He Y, et al. The combination of the lung cancer. Medicine (Baltimore). 2020;99(4):e18607.
blood based tumor biomarkers cytokeratin 19 fragments doi: 10.1097/MD.0000000000018607
(CYFRA 21-1) and carcinoembryonic antigen (CEA) as a
potential predictor of benefit from adjuvant chemotherapy 22. Li X, Qin S, Sun X, et al. Prognostic significance of albumin-
in early stage squamous cell carcinoma of the lung (SCC). globulin score in patients with operable non-small-cell lung
Lung Cancer. 2018;120:46-53. cancer. Ann Surg Oncol. 2018;25(12):3647-3659.
doi: 10.1016/j.lungcan.2018.03.015 doi: 10.1245/s10434-018-6715-z
13. Niklinski J, Furman M, Burzykowski T, et al. Preoperative 23. Okugawa Y, Toiyama Y, Yamamoto A, et al. Lymphocyte-
CYFRA 21-1 level as a prognostic indicator in resected C-reactive protein ratio as promising new marker for
primary squamous cell lung cancer. Br J Cancer. predicting surgical and oncological outcomes in colorectal
1996;74(6):956-960. cancer. Ann. Surg. 2020;272(2):342-351.
doi: 10.1038/bjc.1996.464 doi: 10.1097/SLA.0000000000003239
14. Holdenrieder S, Wehnl B, Hettwer K, Simon K, Uhlig S, 24. Yang R, Chang Q, Meng X, Gao N, Wang W. Prognostic
Dayyani F. Carcinoembryonic antigen and cytokeratin-19 value of systemic immune-inflammation index in cancer:
fragments for assessment of therapy response in non-small A meta-analysis. J Cancer. 2018;9(18):3295-3302.
cell lung cancer: A systematic review and meta-analysis. Br J doi: 10.7150/jca.25691
Cancer. 2017;116(8):1037-1045.
25. Dirican N, Dirican A, Anar C, et al. New inflammatory
doi: 10.1038/bjc.2017.45 prognostic index, based on C-reactive protein, the
15. Svaton M, Blazek J, Krakorova G, et al. Prognostic role neutrophil to lymphocyte ratio and serum albumin is useful
for CYFRA 21-1 in patients with advanced-stage NSCLC for predicting prognosis in non-small cell lung cancer cases.
treated with bevacizumab plus chemotherapy. Anticancer Asian Pac J Cancer Prev. 2016;17(12):5101-5106.
Res. 2021;41(4):2053-2058. doi: 10.22034/APJCP.2016.17.12.5101
doi: 10.21873/anticanres.14974 26. Wang Y, Hu X, Xu W, Wang H, Huang Y, Che G. Prognostic
16. Baek AR, Seo HJ, Lee JH, et al. Prognostic value of baseline value of a novel scoring system using inflammatory response
carcinoembryonic antigen and cytokeratin 19 fragment biomarkers in non-small cell lung cancer: A retrospective
levels in advanced non-small cell lung cancer. Cancer study. Thorac Cancer. 2019;10(6):1402-1411.
Biomark. 2018;22(1):55-62. doi: 10.1111/1759-7714.13085
doi: 10.3233/CBM-170885 27. van den Heuvel M, Holdenrieder S, Schuurbiers M,
17. Vodicka J, Skala M, Sebek J, et al. The role of serum tumor et al. Serum tumor markers for response prediction and
markers in follow-up after surgical treatment of malignant monitoring of advanced lung cancer: A review focusing
lung tumors. Anticancer Res. 2021;41(10):5117-5122. on immunotherapy and targeted therapies. Tumour Biol.
2024;46(S1):S233-S268.
doi: 10.21873/anticanres.15328
doi: 10.3233/TUB-220039
18. Zhang J, Huang SH, Li H, et al. Preoperative lymphocyte
count is a favorable prognostic factor of disease-free 28. Wang BY, Huang JY, Chen HC, et al. The comparison between
survival in non-small-cell lung cancer. J Med Oncol. adenocarcinoma and squamous cell carcinoma in lung
2013;30(1):352-357. cancer patients. J Cancer Res Clin Oncol. 2020;146(1):43-52.

Volume 3 Issue 4 (2024) 13 doi: 10.36922/gtm.4865